Mostra i principali dati dell'item

dc.creatorLioutas V.-A., Goyal N., Katsanos A.H., Krogias C., Zand R., Sharma V.K., Varelas P., Malhotra K., Paciaroni M., Sharaf A., Chang J., Karapanayiotides T., Kargiotis O., Pappa A., Mai J., Pandhi A., Schroeder C., Tsantes A., Mehta C., Kerro A., Khan A., Mitsias P.D., Selim M.H., Alexandrov A.V., Tsivgoulis G.en
dc.date.accessioned2023-01-31T08:55:14Z
dc.date.available2023-01-31T08:55:14Z
dc.date.issued2018
dc.identifier10.1161/STROKEAHA.118.021979
dc.identifier.issn00392499
dc.identifier.urihttp://hdl.handle.net/11615/75943
dc.description.abstractBackground and Purpose: The aim of this study was to prospectively validate our prior findings of smaller hematoma volume and lesser neurological deficit in nonvitamin K oral anticoagulant (NOAC) compared with Vitamin K antagonist (VKA)-related intracerebral hemorrhage (ICH). Methods: Prospective 12-month observational study in 15 tertiary stroke centers in the United States, Europe, and Asia. Consecutive patients with premorbid modified Rankin Scale score of <2 with acute nontraumatic anticoagulant-related ICH divided into 2 groups according to the type of anticoagulant: NOAC versus VKA. We recorded baseline ICH volume, significant hematoma expansion (absolute [12.5 mL] or relative [>33%] increase), neurological severity measured by National Institutes of Health Stroke Scale score, 90-day mortality, and functional status (modified Rankin Scale score). Results: Our cohort comprised 196 patients, 62 NOAC related (mean age, 75.0±11.4 years; 54.8% men) and 134 VKA related (mean age, 72.3±10.5; 73.1% men). There were no differences in vascular comorbidities, antiplatelet, and statin use; NOAC-related ICH patients had lower median baseline hematoma volume (13.8 [2.5-37.6] versus 19.5 [6.6-52.0] mL; P=0.026) and were less likely to have severe neurological deficits (National Institutes of Health Stroke Scale score of >10 points) on admission (37% versus 55.3%, P=0.025). VKA-ICH were more likely to have significant hematoma expansion (37.4% versus 17%, P=0.008). NOAC pretreatment was independently associated with smaller baseline hematoma volume (standardized linear regression coefficient:−0.415 [95% CI, −0.780 to −0.051]) resulting in lower likelihood of severe neurological deficit (odds ratio, 0.44; 95% CI, 0.22−0.85) in multivariable-adjusted models. Conclusions-Patients with NOAC-related ICH have smaller baseline hematoma volumes and lower odds of severe neurological deficit compared with VKA-related ICH. These findings are important for practicing clinicians making anticoagulation choices. © 2018 American Heart Association, Inc.en
dc.language.isoenen
dc.sourceStrokeen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85055606682&doi=10.1161%2fSTROKEAHA.118.021979&partnerID=40&md5=d0d4145d0cdeb022fb908eea9a6fa9ad
dc.subjectandexanet alfaen
dc.subjectanticoagulant agenten
dc.subjectantithrombocytic agenten
dc.subjectantivitamin Ken
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitoren
dc.subjectidarucizumaben
dc.subjectanticoagulant agenten
dc.subjectvitamin K groupen
dc.subjectwarfarinen
dc.subjectageden
dc.subjectbrain hematomaen
dc.subjectbrain hemorrhageen
dc.subjectclinical outcomeen
dc.subjectcohort analysisen
dc.subjectcomorbidityen
dc.subjectConference Paperen
dc.subjectfemaleen
dc.subjecthumanen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmortalityen
dc.subjectmultivariate analysisen
dc.subjectNational Institutes of Health Stroke Scaleen
dc.subjectneuroimagingen
dc.subjectobservational studyen
dc.subjectpriority journalen
dc.subjectprospective studyen
dc.subjectRankin scaleen
dc.subjecttertiary care centeren
dc.subjectbrain hemorrhageen
dc.subjecthematomaen
dc.subjectmiddle ageden
dc.subjectoral drug administrationen
dc.subjecttreatment outcomeen
dc.subjectvery elderlyen
dc.subjectAdministration, Oralen
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAnticoagulantsen
dc.subjectCerebral Hemorrhageen
dc.subjectFemaleen
dc.subjectHematomaen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeuroimagingen
dc.subjectProspective Studiesen
dc.subjectTreatment Outcomeen
dc.subjectVitamin Ken
dc.subjectWarfarinen
dc.subjectLippincott Williams and Wilkinsen
dc.titleClinical outcomes and neuroimaging profiles in nondisabled patients with anticoagulant-related intracerebral hemorrhageen
dc.typeconferenceItemen


Files in questo item

FilesDimensioneFormatoMostra

Nessun files in questo item.

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item